Drug Trial Radar · NCT04178577
Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function
Last checked: Nov 19, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Dec 6, 2019
Primary completion
Sep 6, 2020
Study completion Sep 11, 2020
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.
Conditions
- Renal Impairment
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)Drug
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Apparent total body clearance (CL/F).Time frame: 72 hours post dose
- Area under the curve from time zero to the last quantifiable sample (AUC0-last).Time frame: 72 hours post dose
- Area under the curve extrapolated to infinity (AUC0-∞).Time frame: 72 hours post dose
- Apparent steadystate volume of distribution (Vss/F).Time frame: 72 hours post dose
- Maximum plasma concentration (Cmax).Time frame: 72 hours post dose
- Time to the maximum plasma concentration (Tmax).Time frame: 72 hours post dose
- Terminal elimination half-life (t1/2).Time frame: 72 hours post dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Medical Facility
Miami, Florida
Medical Facility
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.